Supplementary Material

Figure S1. The definition of tolvaptan dose reduction or discontinuation




Figure S2. Methods of evaluating major adverse effects




Figure S3. Sensitivity analysis: factors associated with tolvaptan dose reduction or discontinuation using eGFR

P-values


0.63


0.33

0.002

0.36

0.17








Table S1. Frequency of major adverse effects

Variables	Overall
Overall	n=156
Elevation in aminotransferase, n (%)	6 (3.8)
To > 3×ULN	6 (3.8)
To > 5×ULN	5 (3.2)
To > 10×ULN	4 (2.6)
Missing data	20 (13)
Hypernatremia, n (%)	12 (7.7)
To > 145 mEq/L	12 (7.7)
To > 150 mEq/L	1 (0.64)
To > 160 mEq/L	0 (0)
Missing data	11 (7.1)
Acute kidney injury, n (%)	6 (3.8)
To > 1.5×Baseline serum creatinine	6 (3.8)
$To > 2.0 \times Baseline$ serum creatinine	5 (3.2)
$To > 3.0 \times Baseline$ serum creatinine	2 (1.3)
Missing data	20 (13)

Data were presented as unweighted number (percentage) of patients. Abbreviations: ULN, Upper Limit of the Normal Range